Anti-Human IL-17A Recombinant Antibody (SAA0386), APC (HS856137)

Name: Anti-Human IL-17A Recombinant Antibody (SAA0386), APC
Brand: abinScience
SKU: HS856137
Price: 256 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

50T
100T

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HS856137
Reactivité des espèces	Human
Applications	ELISA, FCM
Espèce hôte	Mouse
Clonalité	Monoclonal
Isotype	IgG1, kappa
ID de clone	SAA0386
Conjugaison	APC
Cible	CTLA-8, CTLA8, Cytotoxic T-lymphocyte-associated antigen 8, IL-17, IL-17A, IL17, IL17A, Interleukin-17A
Niveau d'endotoxines	Please contact with the lab for this information.
Pureté	>90% as determined by SDS-PAGE.
Produits associés	Mouse IgG1, kappa Recombinant Isotype Control Antibody (MOPC-21), APC
Numéro d'accès	Q16552
Forme	Liquid
Tampon de stockage	0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Store at 4°C for 12 months. Protect from light. Do not freeze.
Contexte	Interleukin-17A (IL17A) is a ~17 kDa protein. Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. IL17A is the therapeutic target of secukinumab (Cosentyx). 1. Boisson, B. et al. (2013) Immunity 39, 676-86. PMID: 24120361 2. Kuestner, RE. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 5462-73. PMID: 17911633 3. Wright, JF. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 2799-805. PMID: 18684971 4. Liu, C. et al. (2009) Science signaling 2, ra63. PMID: 19825828 5. Puel, A. et al. (2011) Science (New York, N.Y.) 332, 65-8. PMID: 21350122 6. Fossiez, F. et al. (1996) The Journal of experimental medicine 183, 2593-603. PMID: 8676080
Note	For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only.